Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096616 | 0.89 | KDM1A (0.36) | S1PR5 | |
| SCHEMBL6099163 | 0.86 | MCL1 (0.43) | S1PR5HTR7MCL1BCL2BCL2L1 | |
| SCHEMBL6099479 | 0.83 | HRH3 (0.39) | HTTHRH3 | |
| SCHEMBL6095694 | 0.80 | TDP1 (0.42) | S1PR5 | |
| SCHEMBL6097342 | 0.79 | KDM4E (0.48) | HTT | |
| SCHEMBL6097732 | 0.78 | SMN1; SMN2 (0.45) | MCL1HTT | |
| SCHEMBL6099016 | 0.77 | HTR7 (0.40) | S1PR5HTR7MCL1BCL2BCL2L1 | |
| SCHEMBL6097566 | 0.74 | — | — | |
| SCHEMBL6096133 | 0.70 | P2RX3 (0.41) | SSTR4 | |
| SCHEMBL6096847 | 0.69 | ALDH1A1 (0.44) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022694-B2 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1406902-B1 | HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1406902-A1 | HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003006466-A1 | HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | TPH1, HTR5A, TPH2 | S1PR5 141/4885HTR7 7/4885MCL1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.